TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.

VINCENT, a TIM3-targeted nanoformulation, overcomes venetoclax resistance and reactivates NK cells in AML, showing efficacy in resistant models and patient samples.

• Why it matters: AML treatment remains difficult, especially for older or unfit patients who develop resistance to venetoclax, highlighting the need for targeted therapies that can overcome resistance and restore immune function.
• What they did: A novel therapeutic platform called VINCENT was developed, combining anti-CD16, anti-TIM3 antibodies, and nanoformulated venetoclax, tested on resistant AML cell lines, patient-derived xenografts, and primary samples.
• The result: VINCENT effectively kills resistant blasts, enhances NK cell activity, and remodels the immune microenvironment, providing a personalized approach for AML patients failing standard venetoclax therapy.